Cargando…

Apremilast, a novel phosphodiesterase 4 (PDE4) inhibitor, regulates inflammation through multiple cAMP downstream effectors

INTRODUCTION: This work was undertaken to delineate intracellular signaling pathways for the PDE4 inhibitor apremilast and to examine interactions between apremilast, methotrexate and adenosine A(2A) receptors (A(2A)R). METHODS: After apremilast and LPS incubation, intracellular cAMP, TNF-α, IL-10,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Perez-Aso, Miguel, Montesinos, M. Carmen, Mediero, Aránzazu, Wilder, Tuere, Schafer, Peter H., Cronstein, Bruce
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4570588/ https://www.ncbi.nlm.nih.gov/pubmed/26370839 http://dx.doi.org/10.1186/s13075-015-0771-6

Ejemplares similares

Impact of phosphodiesterases PDE3 and PDE4 on 5-hydroxytryptamine receptor4-mediated increase of cAMP in human atrial fibrillation
por: Dolce, Bernardo, et al.
Publicado: (2020)

Pharmacophore Modeling and Virtual Screening for the Discovery of New type 4 cAMP Phosphodiesterase (PDE4) Inhibitors
por: Niu, Miaomiao, et al.
Publicado: (2013)

The antiviral drug tenofovir, an inhibitor of Pannexin-1-mediated ATP release, prevents liver and skin fibrosis by downregulating adenosine levels in the liver and skin
por: Feig, Jessica L., et al.
Publicado: (2017)

PDE4-Mediated cAMP Signalling
por: Fertig, Bracy A., et al.
Publicado: (2018)

Dominant-Negative Attenuation of cAMP-Selective Phosphodiesterase PDE4D Action Affects Learning and Behavior
por: Bolger, Graeme B., et al.
Publicado: (2020)

The Complexity and Multiplicity of the Specific cAMP Phosphodiesterase Family: PDE4, Open New Adapted Therapeutic Approaches
por: Lugnier, Claire
Publicado: (2022)

Chemical informatics uncovers a new role for moexipril as a novel inhibitor of cAMP phosphodiesterase-4 (PDE4)
por: Cameron, Ryan T., et al.
Publicado: (2013)

Dimerization of cAMP phosphodiesterase-4 (PDE4) in living cells requires interfaces located in both the UCR1 and catalytic unit domains
por: Bolger, Graeme B., et al.
Publicado: (2015)

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor: A novel treatment option for nurse practitioners treating patients with psoriatic disease
por: Young, Melodie, et al.
Publicado: (2016)

Cigarette smoke up‐regulates PDE3 and PDE4 to decrease cAMP in airway cells
por: Zuo, Haoxiao, et al.
Publicado: (2018)

Small-molecule allosteric activators of PDE4 long form cyclic AMP phosphodiesterases
por: Omar, Faisa, et al.
Publicado: (2019)

An evolutionary analysis of cAMP-specific Phosphodiesterase 4 alternative splicing
por: Johnson, Keven R, et al.
Publicado: (2010)

The cAMP phosphodiesterase-4D7 (PDE4D7) is downregulated in androgen-independent prostate cancer cells and mediates proliferation by compartmentalising cAMP at the plasma membrane of VCaP prostate cancer cells
por: Henderson, D J P, et al.
Publicado: (2014)

Apremilast: A Phosphodiesterase 4 Inhibitor for the Treatment of Psoriatic Arthritis
por: Mease, Philip J.
Publicado: (2014)

Phosphodiesterases and cAMP Pathway in Pituitary Diseases
por: Bizzi, Mariana Ferreira, et al.
Publicado: (2019)

The activity of cAMP-phosphodiesterase 4D7 (PDE4D7) is regulated by protein kinase A-dependent phosphorylation within its unique N-terminus
por: Byrne, Ashleigh M., et al.
Publicado: (2015)

PdeH, a High-Affinity cAMP Phosphodiesterase, Is a Key Regulator of Asexual and Pathogenic Differentiation in Magnaporthe oryzae
por: Ramanujam, Ravikrishna, et al.
Publicado: (2010)

Erratum to: Apremilast: A Phosphodiesterase 4 Inhibitor for the Treatment of Psoriatic Arthritis
por: Mease, Philip J.
Publicado: (2015)

Phosphodiesterase 4 inhibitor apremilast improves insulin resistance in psoriasis patients
por: Ikumi, Kyoko, et al.
Publicado: (2021)

Atropine augments cardiac contractility by inhibiting cAMP-specific phosphodiesterase type 4
por: Perera, Ruwan K., et al.
Publicado: (2017)

PDE4 and Epac1 Synergistically Promote Rectal Carcinoma via the cAMP Pathway
por: Kong, Xiangyu, et al.
Publicado: (2019)

Delineation of RAID1, the RACK1 interaction domain located within the unique N-terminal region of the cAMP-specific phosphodiesterase, PDE4D5
por: Bolger, Graeme B, et al.
Publicado: (2002)

Retraction for Baillie et al., β-Arrestin-mediated PDE4 cAMP phosphodiesterase recruitment regulates β-adrenoceptor switching from G(s) to G(i)
Publicado: (2022)

Mitochondrial Complex I Core Protein Regulates cAMP Signaling via Phosphodiesterase Pde2 and NAD Homeostasis in Candida albicans
por: She, Xiaodong, et al.
Publicado: (2020)

Phosphodiesterase (PDE) III inhibitor, Cilostazol, improved memory impairment in aluminum chloride-treated rats: modulation of cAMP/CREB pathway
por: Khalifa, Mona, et al.
Publicado: (2022)

Phosphodiesterase (PDE)-4 Inhibitors and COPD Correlation with Cancer
por: Organtzis, John, et al.
Publicado: (2014)

The Role of Type 4 Phosphodiesterases in Generating Microdomains of cAMP: Large Scale Stochastic Simulations
por: Oliveira, Rodrigo F., et al.
Publicado: (2010)

Phosphodiesterase type 4 anchoring regulates cAMP signaling to Popeye domain-containing proteins
por: Tibbo, Amy J., et al.
Publicado: (2022)

Interaction with receptor for activated C-kinase 1 (RACK1) sensitizes the phosphodiesterase PDE4D5 towards hydrolysis of cAMP and activation by protein kinase C
por: Bird, Rebecca J., et al.
Publicado: (2010)

Overexpression of PDE4A Acts as Checkpoint Inhibitor Against cAMP-Mediated Immunosuppression in vitro
por: Schmetterer, Klaus G., et al.
Publicado: (2019)

Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast
por: Gooderham, Melinda, et al.
Publicado: (2015)

Inhaled Phosphodiesterase 4 (PDE4) Inhibitors for Inflammatory Respiratory Diseases
por: Phillips, Jonathan E.
Publicado: (2020)

Correction to: Phosphodiesterase (PDE) III inhibitor, Cilostazol, improved memory impairment in aluminum chloride-treated rats: modulation of cAMP/CREB pathway
por: Khalifa, Mona, et al.
Publicado: (2022)

Imaging of PDE2- and PDE3-Mediated cGMP-to-cAMP Cross-Talk in Cardiomyocytes
por: Pavlaki, Nikoleta, et al.
Publicado: (2018)

Rolipram, a Phosphodiesterase 4 Inhibitor, Stimulates Inducible cAMP Early Repressor Expression in Osteoblasts
por: Cho, Eun Sook, et al.
Publicado: (2005)

DISC1–ATF4 transcriptional repression complex: dual regulation of the cAMP-PDE4 cascade by DISC1
por: Soda, T, et al.
Publicado: (2013)

Type-4 Phosphodiesterase (PDE4) Blockade Reduces NETosis in Cystic Fibrosis
por: Totani, Licia, et al.
Publicado: (2021)

cAMP-PDE signaling in COPD: Review of cellular, molecular and clinical features
por: Nourian, Yazdan Hasani, et al.
Publicado: (2023)

PKA and PDE4D3 anchoring to AKAP9 provides distinct regulation of cAMP signals at the centrosome
por: Terrin, Anna, et al.
Publicado: (2012)

The protective effect of the PDE-4 inhibitor rolipram on intracerebral haemorrhage is associated with the cAMP/AMPK/SIRT1 pathway
por: Dong, Xiao-Liu, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_e7va8863mn05c9bg9agi1566g8